The most common adverse events during phase @ were weight increase ( @ % ) , somnolence ( @ % ) , and vomiting ( @ % ) ; and , during phase @ ( aripiprazole vs placebo ) , they were upper respiratory tract infection ( @ % vs @ % ) , constipation ( @ % vs @ % ) , and movement disorder ( @ % vs @ % ) .